Top

Published in:

Open Access 01-12-2010 | Research article

Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors

Authors: JiaJia Huang, WenQi Jiang, RuiHua Xu, HuiQiang Huang, Yue Lv, ZhongJun Xia, XiaoFei Sun, ZhongZhen Guan, TongYu Lin, ZhiMing Li

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

Optimal management and outcome of primary gastric lymphoma (PGL) have not been well defined in the rituximab era. This study aimed to analyze the clinical characteristics, prognostic factors, and roles of different treatment modalities in Chinese patients with PGL.

Methods

The clinicopathological features of 83 Chinese patients with PGL were retrospectively reviewed. Staging was performed according to the Lugano staging system for gastrointestinal non-Hodgkin's lymphoma.

Results

The predominant pathologic subtype among Chinese patients with PGL in our study was diffuse large B cell lymphoma (DLBCL), followed by mucosa-associated lymphoid tissue (MALT) lymphoma. Among the 57 patients with gastric DLBCL, 20 patients (35.1%) were classified as the germinal center B cell-like (GCB) subtype and 37 patients (64.9%) as the non-GCB subtype. The 83 patients had a five-year overall survival (OS) and event-free survival (EFS) of 52% and 59%, respectively. Cox regression analysis showed that stage-modified international prognostic index (IPI) and performance status (PS) were independent predictors of survival. In the 67 B-cell lymphoma patients who received chemotherapy, 36 patients treated with rituximab (at least 3 cycles) had a mean OS of 72 months (95% CI 62-81) versus 62 months (95% CI 47-76) for patients without rituximab treatment (P = 0.021).

Conclusion

The proportion of Chinese gastric DLBCL cases with non-GCB subtype was higher than the GCB subtype. Stage-modified IPI and PS were effective prognostic factors in Chinese patients with PGL. Our data suggested that primary gastric B-cell lymphoma might have an improved outcome with rituximab in addition to chemotherapy. More studies are necessary, preferentially large prospective randomized clinical trials to obtain more information on the impact of the rituximab in the primary gastric B-cell lymphoma.

Available only for authorised users

Ferreri AJ, Montalban C: Primary diffuse large B-cell lymphoma of the stomach. Critical reviews in oncology/hematology. 2007, 63 (1): 65-71. 10.1016/j.critrevonc.2007.01.003.CrossRefPubMed

Dawson IM, Cornes JS, Morson BC: Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. The British journal of surgery. 1961, 49: 80-89. 10.1002/bjs.18004921319.CrossRefPubMed

Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leukemia & lymphoma. 2006, 47 (10): 2140-2146.CrossRef

Medina-Franco H, Germes SS, Maldonado CL: Prognostic factors in primary gastric lymphoma. Annals of surgical oncology. 2007, 14 (8): 2239-2245. 10.1245/s10434-006-9244-0.CrossRefPubMed

d'Amore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS: Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol. 1994, 12 (8): 1673-1684.PubMed

Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, et al: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001, 19 (18): 3861-3873.PubMed

Chan JK: The new World Health Organization classification of lymphomas: the past, the present and the future. Hematological oncology. 2001, 19 (4): 129-150. 10.1002/hon.660.CrossRefPubMed

Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M, et al: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994, 5 (5): 397-400.PubMed

Santacroce L, Cagiano R, Del Prete R, Bottalico L, Sabatini R, Carlaio RG, Prejbeanu R, Vermesan H, Dragulescu SI, Vermesan D, et al: Helicobacter pylori infection and gastric MALTomas: an up-to-date and therapy highlight. La Clinica terapeutica. 2008, 159 (6): 457-462.PubMed

10.

Wundisch T, Kim TD, Thiede C, Morgner A, Alpen B, Stolte M, Neubauer A: Etiology and therapy of Helicobacter pylori-associated gastric lymphomas. Annals of hematology. 2003, 82 (9): 535-545. 10.1007/s00277-003-0677-2.CrossRefPubMed

11.

Psyrri A, Papageorgiou S, Economopoulos T: Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008, 19 (12): 1992-1999. 10.1093/annonc/mdn525.CrossRefPubMedPubMedCentral

12.

Lewin KJ, Ranchod M, Dorfman RF: Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer. 1978, 42 (2): 693-707. 10.1002/1097-0142(197808)42:2<693::AID-CNCR2820420241>3.0.CO;2-J.CrossRefPubMed

13.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004, 103 (1): 275-282. 10.1182/blood-2003-05-1545.CrossRefPubMed

14.

Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pasini F, Pinotti G, Bertini M, et al: Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 1999, 10 (12): 1433-1440. 10.1023/A:1008351427601.CrossRefPubMed

15.

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999, 17 (4): 1244-PubMed

16.

Ferrucci PF, Zucca E: Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?. British journal of haematology. 2007, 136 (4): 521-538. 10.1111/j.1365-2141.2006.06444.x.CrossRefPubMed

17.

Chen YW, Hu XT, Liang AC, Au WY, So CC, Wong ML, Shen L, Tao Q, Chu KM, Kwong YL, et al: High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood. 2006, 108 (7): 2373-2383. 10.1182/blood-2006-05-022517.CrossRefPubMed

18.

Nakamura S, Ye H, Bacon CM, Goatly A, Liu H, Kerr L, Banham AH, Streubel B, Yao T, Tsuneyoshi M, et al: Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. Clin Cancer Res. 2008, 14 (10): 3002-3010. 10.1158/1078-0432.CCR-07-4946.CrossRefPubMed

19.

Hussell T, Isaacson PG, Crabtree JE, Spencer J: The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 1993, 342 (8871): 571-574. 10.1016/0140-6736(93)91408-E.CrossRefPubMed

20.

Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST: Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Annals of hematology. 2009, 88 (5): 417-424. 10.1007/s00277-008-0604-7.CrossRefPubMed

21.

Mok TS, Steinberg J, Chan AT, Yeo WM, Hui P, Leung TW, Johnson P: Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. Cancer. 1998, 82 (12): 2439-2448. 10.1002/(SICI)1097-0142(19980615)82:12<2439::AID-CNCR19>3.0.CO;2-Q.CrossRefPubMed

22.

Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, et al: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005, 23 (28): 7050-7059. 10.1200/JCO.2005.04.031.CrossRefPubMed

23.

Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, et al: Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001, 19 (18): 3874-3883.PubMed

24.

Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M: Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Archives of dermatological research. 2009, 301 (9): 689-692. 10.1007/s00403-009-0967-1.CrossRefPubMed

25.

Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E: Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert opinion on biological therapy. 2009, 9 (2): 207-220. 10.1517/14712590802650581.CrossRefPubMed

26.

Zhou X, Hu W, Qin X: The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. The oncologist. 2008, 13 (9): 954-966. 10.1634/theoncologist.2008-0089.CrossRefPubMed

27.

Wohrer S, Puspok A, Drach J, Hejna M, Chott A, Raderer M: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol. 2004, 15 (7): 1086-1090. 10.1093/annonc/mdh261.CrossRefPubMed

28.

Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima Y: Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. European journal of haematology. 2010, 84 (6): 493-498. 10.1111/j.1600-0609.2010.01426.x.CrossRefPubMed

29.

Aviles A, Castaneda C, Cleto S, Neri N, Huerta-Guzman J, Gonzalez M, Nambo MJ: Rituximab and chemotherapy in primary gastric lymphoma. Cancer biotherapy & radiopharmaceuticals. 2009, 24 (1): 25-28.CrossRef

30.

Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, et al: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005, 23 (9): 1979-1983. 10.1200/JCO.2005.08.128.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/358/prepub

Title: Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors
Authors: JiaJia Huang
WenQi Jiang
RuiHua Xu
HuiQiang Huang
Yue Lv
ZhongJun Xia
XiaoFei Sun
ZhongZhen Guan
TongYu Lin
ZhiMing Li
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-358

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients

Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole

Self-reported history of Pap-smear in HIV-positive women in Northern Italy: a cross-sectional study

Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers

Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine

In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer